Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immunotherapy

Tumor-infiltrating T cells—ready for prime time in melanoma?

Nature Reviews Clinical Oncology volume 8, pages 449–450 (2011)Cite this article

Subjects

Data from three phase II trials of tumor-infiltrating lymphocytes demonstrate high and durable complete response rates in patients with stage IV melanoma. Improved clinical outcomes might be achieved by combining tumor-infiltrating lymphocytes with other novel immunotherapeutic agents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Aptsiauri, N. et al. MHC class I antigens and immune surveillance in transformed cells. Int. Rev. Cytol. 256, 139–189 (2007).

    Article  CAS  Google Scholar 

  2. Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233–5239 (2008).

    Article  CAS  Google Scholar 

  3. Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin. Cancer Res. doi:10.1158/1078–0432ccr-11-0116.

  4. Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199–6206 (2009).

    Article  Google Scholar 

  5. Middleton, M. R. et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18, 158–166 (2000).

    Article  CAS  Google Scholar 

  6. Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).

    Article  CAS  Google Scholar 

  7. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    Article  CAS  Google Scholar 

  8. Chapman, P. B. et al. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma [abstract]. J. Clin. Oncol. 29 (15 Suppl.), LBA4 (2011).

    Google Scholar 

  9. Natarajan, N., Telang, S., Miller, D. M. & Chesney, J. Novel immunotherapeutic agents and small molecule antagonists of signaling kinases for the treatment of metastatic melanoma. Drugs (in press).

  10. Rasku, M. A. et al. Transient T cell depletion causes regression of melanoma metastases. J. Transl. Med. 6, 12 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Medicine, University of Louisville School of Medicine, 505 South Hancock Street, Room #424, Louisville, 40202, KY, USA

    Jason Chesney

  2. Department of Surgery, University of Louisville School of Medicine, 505 South Hancock Street, Room #424, Louisville, 40202, KY, USA

    Kelly M. McMasters

Authors
  1. Jason Chesney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly M. McMasters
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason Chesney.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chesney, J., McMasters, K. Tumor-infiltrating T cells—ready for prime time in melanoma?. Nat Rev Clin Oncol 8, 449–450 (2011). https://doi.org/10.1038/nrclinonc.2011.103

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.103

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing